Skin Barrier Function and Atopic Dermatitis

1.

Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–22. https://doi.org/10.1016/s0140-6736(15)00149-x.CrossRefPubMed

2.

Wallach D, Taieb A. Atopic dermatitis/atopic eczema. Chem Immunol Allergy. 2014;100:81–96. https://doi.org/10.1159/000358606.CrossRefPubMed

3.

Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145–51. https://doi.org/10.1111/j.1365-2133.2006.07185.x.CrossRefPubMed

4.

Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–7. https://doi.org/10.1111/jdv.13689.CrossRefPubMed

5.

Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94. https://doi.org/10.1056/NEJMra074081.CrossRefPubMed

6.

Alduraywish SA, Lodge CJ, Campbell B, Allen KJ, Erbas B, Lowe AJ, et al. The march from early life food sensitization to allergic disease: a systematic review and meta-analyses of birth cohort studies. Allergy. 2016;71(1):77–89. https://doi.org/10.1111/all.12784.CrossRefPubMed

7.

Saunders SP, Moran T, Floudas A, Wurlod F, Kaszlikowska A, Salimi M, et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol. 2016;137(2):482–91. https://doi.org/10.1016/j.jaci.2015.06.045.CrossRefPubMedPubMedCentral

8.

Lee HJ, Lee NR, Kim BK, Jung M, Kim DH, Moniaga CS, et al. Acidification of stratum corneum prevents the progression from atopic dermatitis to respiratory allergy. Exp Dermatol. 2017;26(1):66–72. https://doi.org/10.1111/exd.13144.CrossRefPubMed

9.

•• Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z. This article briefly summarizes the overview in every aspect of atopic dermatitis. CrossRefPubMed

10.

Tang TS, Bieber T, Williams HC. Does “autoreactivity” play a role in atopic dermatitis? J Allergy Clin Immunol. 2012;129(5):1209–15.e2. https://doi.org/10.1016/j.jaci.2012.02.002.CrossRefPubMed

11.

Nygaard U, Riis JL, Deleuran M, Vestergaard C. Attention-deficit/hyperactivity disorder in atopic dermatitis: an appraisal of the current literature. Pediatric Allergy, Immunology, and Pulmonology. 2016;29(4):181–8. https://doi.org/10.1089/ped.2016.0705.CrossRef

12.

Schmitt J, Schwarz K, Baurecht H, Hotze M, Folster-Holst R, Rodriguez E, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–6. https://doi.org/10.1016/j.jaci.2015.06.029.CrossRefPubMed

13.

Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017;76(2):274–80.e1. https://doi.org/10.1016/j.jaad.2016.08.047.CrossRefPubMed

14.

Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522–8. https://doi.org/10.1001/jamadermatol.2014.3324.CrossRefPubMed

15.

Andersen YMF, Egeberg A, Skov L, Thyssen JP. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep. 2017;6(1):35–41. https://doi.org/10.1007/s13671-017-0168-7.CrossRefPubMedPubMedCentral

16.

Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14. https://doi.org/10.1186/s41232-017-0044-7.CrossRefPubMedPubMedCentral

17.

Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev. 2017;278(1):246–62. https://doi.org/10.1111/imr.12545.CrossRefPubMed

18.

Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6):269–80. https://doi.org/10.1093/intimm/dxv013.CrossRefPubMed

19.

Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018;67(1):3–11. https://doi.org/10.1016/j.alit.2017.10.002.CrossRefPubMed

20.

Wallace L, Roberts-Thompson L, Reichelt J. Deletion of K1/K10 does not impair epidermal stratification but affects desmosomal structure and nuclear integrity. J Cell Sci. 2012;125(Pt 7):1750–8. https://doi.org/10.1242/jcs.097139.CrossRefPubMed

21.

Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–8.e1. https://doi.org/10.1016/j.jaci.2016.06.002.CrossRefPubMed

22.

Leyvraz C, Charles RP, Rubera I, Guitard M, Rotman S, Breiden B, et al. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol. 2005;170(3):487–96. https://doi.org/10.1083/jcb.200501038.CrossRefPubMedPubMedCentral

23.

Matsui T, Miyamoto K, Kubo A, Kawasaki H, Ebihara T, Hata K, et al. SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol Med. 2011;3(6):320–33. https://doi.org/10.1002/emmm.201100140.CrossRefPubMedPubMedCentral

24.

Egawa G, Doi H, Miyachi Y, Kabashima K. Skin tape stripping and cheek swab method for a detection of filaggrin. J Dermatol Sci. 2013;69(3):263–5. https://doi.org/10.1016/j.jdermsci.2012.12.004.CrossRefPubMed

25.

Nachat R, Mechin MC, Takahara H, Chavanas S, Charveron M, Serre G, et al. Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J Invest Dermatol. 2005;124(2):384–93. https://doi.org/10.1111/j.0022-202X.2004.23568.x.CrossRefPubMed

26.

Scharschmidt TC, List K, Grice EA, Szabo R, Renaud G, Lee CC, et al. Matriptase-deficient mice exhibit ichthyotic skin with a selective shift in skin microbiota. J Invest Dermatol. 2009;129(10):2435–42. https://doi.org/10.1038/jid.2009.104.CrossRefPubMedPubMedCentral

27.

Manabe M, Sanchez M, Sun TT, Dale BA. Interaction of filaggrin with keratin filaments during advanced stages of normal human epidermal differentiation and in ichthyosis vulgaris. Differentiation. 1991;48(1):43–50.CrossRefPubMed

28.

Simonsen S, Thyssen JP, Heegaard S, Kezic S, Skov L. Expression of filaggrin and its degradation products in human skin following erythemal doses of ultraviolet B irradiation. Acta Derm Venereol. 2017;97(7):797–801. https://doi.org/10.2340/00015555-2662.CrossRefPubMed

29.

Gibbs NK, Tye J, Norval M. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem Photobiol Sci. 2008;7(6):655–67. https://doi.org/10.1039/b717398a.CrossRefPubMed

30.

Hoste E, Kemperman P, Devos M, Denecker G, Kezic S, Yau N, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–41. https://doi.org/10.1038/jid.2011.153.CrossRefPubMed

31.

Kamata Y, Taniguchi A, Yamamoto M, Nomura J, Ishihara K, Takahara H, et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem. 2009;284(19):12829–36. https://doi.org/10.1074/jbc.M807908200.CrossRefPubMedPubMedCentral

32.

Kalinin A, Marekov LN, Steinert PM. Assembly of the epidermal cornified cell envelope. J Cell Sci. 2001;114(Pt 17):3069–70.PubMed

33.

Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6(4):328–40. https://doi.org/10.1038/nrm1619.CrossRefPubMed

34.

Candi E, Tarcsa E, Idler WW, Kartasova T, Marekov LN, Steinert PM. Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin. J Biol Chem. 1999;274(11):7226–37.CrossRefPubMed

35.

Feingold KR. Lamellar bodies: the key to cutaneous barrier function. J Invest Dermatol. 2012;132(8):1951–3. https://doi.org/10.1038/jid.2012.177.CrossRefPubMed

36.

Menon GK, Feingold KR, Elias PM. Lamellar body secretory response to barrier disruption. J Invest Dermatol. 1992;98(3):279–89.CrossRefPubMed

37.

Proksch E, Holleran WM, Menon GK, Elias PM, Feingold KR. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol. 1993;128(5):473–82.CrossRefPubMed

38.

Cui L, Jia Y, Cheng ZW, Gao Y, Zhang GL, Li JY, et al. Advancements in the maintenance of skin barrier/skin lipid composition and the involvement of metabolic enzymes. J Cosmet Dermatol. 2016;15(4):549–58. https://doi.org/10.1111/jocd.12245.CrossRefPubMed

39.

Han X. Lipidomics for studying metabolism. Nat Rev Endocrinol. 2016;12(11):668–79. https://doi.org/10.1038/nrendo.2016.98.CrossRefPubMed

40.

Ansari MN, Nicolaides N, Fu HC. Fatty acid composition of the living layer and stratum corneum lipids of human sole skin epidermis. Lipids. 1970;5(10):838–45.CrossRefPubMed

41.

Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta. 2014;1841(3):280–94. https://doi.org/10.1016/j.bbalip.2013.11.007.CrossRefPubMed

42.

Jia Y, Gan Y, He C, Chen Z, Zhou C. The mechanism of skin lipids influencing skin status. J Dermatol Sci. 2018;89(2):112–9. https://doi.org/10.1016/j.jdermsci.2017.11.006.CrossRefPubMed

43.

van Smeden J, Bouwstra JA. Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. Curr Probl Dermatol. 2016;49:8–26. https://doi.org/10.1159/000441540.CrossRefPubMed

44.

Ishida-Yamamoto A, Igawa S, Kishibe M. Molecular basis of the skin barrier structures revealed by electron microscopy. Exp Dermatol. 2018;8:841–46. https://doi.org/10.1111/exd.13674.CrossRefPubMed

45.

Lundstrom A, Serre G, Haftek M, Egelrud T. Evidence for a role of corneodesmosin, a protein which may serve to modify desmosomes during cornification, in stratum corneum cell cohesion and desquamation. Arch Dermatol Res. 1994;286(7):369–75.CrossRefPubMed

46.

Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol. 2005;124(1):198–203. https://doi.org/10.1111/j.0022-202X.2004.23547.x.CrossRefPubMed

47.

Lundstrom A, Egelrud T. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm Venereol. 1991;71(6):471–4.PubMed

48.

Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9):3607–19. https://doi.org/10.1091/mbc.E07-02-0124.CrossRefPubMedPubMedCentral

49.

Kirschner N, Houdek P, Fromm M, Moll I, Brandner JM. Tight junctions form a barrier in human epidermis. Eur J Cell Biol. 2010;89(11):839–42. https://doi.org/10.1016/j.ejcb.2010.07.010.CrossRefPubMed

50.

Brandner JM, Kief S, Grund C, Rendl M, Houdek P, Kuhn C, et al. Organization and formation of the tight junction system in human epidermis and cultured keratinocytes. Eur J Cell Biol. 2002;81(5):253–63. https://doi.org/10.1078/0171-9335-00244.CrossRefPubMed

51.

Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol. 2007;127(11):2525–32. https://doi.org/10.1038/sj.jid.5700865.CrossRefPubMed

52.

• Yokouchi M, Atsugi T, Logtestijn MV, Tanaka RJ, Kajimura M, Suematsu M et al. Epidermal cell turnover across tight junctions based on Kelvin's tetrakaidecahedron cell shape. Elife. 2016;5:e19593. https://doi.org/10.7554/eLife.19593. This article depicted 3D structure of the epidermis in relation to the tight junction.

53.

Kubo A, Nagao K, Yokouchi M, Sasaki H, Amagai M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med. 2009;206(13):2937–46. https://doi.org/10.1084/jem.20091527.CrossRefPubMedPubMedCentral

54.

Yoshida K, Kubo A, Fujita H, Yokouchi M, Ishii K, Kawasaki H, et al. Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):856–64. https://doi.org/10.1016/j.jaci.2014.08.001.CrossRefPubMed

55.

Nakajima S, Igyarto BZ, Honda T, Egawa G, Otsuka A, Hara-Chikuma M, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol. 2012;129(4):1048–55.e6. https://doi.org/10.1016/j.jaci.2012.01.063.CrossRefPubMedPubMedCentral

56.

Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol. 2014;14(6):417–28. https://doi.org/10.1038/nri3683.CrossRefPubMed

57.

Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6. https://doi.org/10.1038/ng1767.CrossRefPubMed

58.

Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–27. https://doi.org/10.1056/NEJMra1011040.CrossRefPubMed

59.

Cai SC, Chen H, Koh WP, Common JE, van Bever HP, McLean WH, et al. Filaggrin mutations are associated with recurrent skin infection in Singaporean Chinese patients with atopic dermatitis. Br J Dermatol. 2012;166(1):200–3. https://doi.org/10.1111/j.1365-2133.2011.10541.x.CrossRefPubMed

60.

Moniaga CS, Egawa G, Kawasaki H, Hara-Chikuma M, Honda T, Tanizaki H, et al. Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol. 2010;176(5):2385–93. https://doi.org/10.2353/ajpath.2010.090957.CrossRefPubMedPubMedCentral

61.

Moniaga CS, Kabashima K. Filaggrin in atopic dermatitis: flaky tail mice as a novel model for developing drug targets in atopic dermatitis. Inflamm Allergy Drug Targets. 2011;10(6):477–85.CrossRefPubMed

62.

Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, et al. Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol. 2016;139:562–71. https://doi.org/10.1016/j.jaci.2016.08.029.CrossRefPubMed

63.

Kawasaki H, Nagao K, Kubo A, Hata T, Shimizu A, Mizuno H, et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol. 2012;129(6):1538–46.e6. https://doi.org/10.1016/j.jaci.2012.01.068.CrossRefPubMed

64.

Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet. 2009;41(5):602–8. https://doi.org/10.1038/ng.358.CrossRefPubMedPubMedCentral

65.

Jeong SK, Kim HJ, Youm JK, Ahn SK, Choi EH, Sohn MH, et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol. 2008;128(8):1930–9. https://doi.org/10.1038/jid.2008.13.CrossRefPubMed

66.

Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol. 2014;133(1):139–46. e1–10. https://doi.org/10.1016/j.jaci.2013.07.027.CrossRefPubMed

67.

Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–62. https://doi.org/10.1038/jid.2011.393.CrossRefPubMed

68.

Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–9. https://doi.org/10.1016/j.jaci.2014.06.014.CrossRefPubMed

69.

Pendaries V, Malaisse J, Pellerin L, Le Lamer M, Nachat R, Kezic S, et al. Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. J Invest Dermatol. 2014;134(12):2938–46. https://doi.org/10.1038/jid.2014.259.CrossRefPubMed

70.

Gruber R, Elias PM, Crumrine D, Lin TK, Brandner JM, Hachem JP, et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. Am J Pathol. 2011;178(5):2252–63. https://doi.org/10.1016/j.ajpath.2011.01.053.CrossRefPubMedPubMedCentral

71.

Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6):1184–90. e3. https://doi.org/10.1016/j.jaci.2010.09.015.CrossRefPubMedPubMedCentral

72.

Mildner M, Jin J, Eckhart L, Kezic S, Gruber F, Barresi C, et al. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. J Invest Dermatol. 2010;130(9):2286–94. https://doi.org/10.1038/jid.2010.115.CrossRefPubMed

73.

Scharschmidt TC, Man MQ, Hatano Y, Crumrine D, Gunathilake R, Sundberg JP, et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol. 2009;124(3):496–506, .e1-6. https://doi.org/10.1016/j.jaci.2009.06.046.CrossRefPubMedPubMedCentral

74.

Brauweiler AM, Bin L, Kim BE, Oyoshi MK, Geha RS, Goleva E, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal alpha-toxin-induced keratinocyte death. J Allergy Clin Immunol. 2013;131(2):421–7. e1–2. https://doi.org/10.1016/j.jaci.2012.10.030.CrossRefPubMed

75.

Matsui S, Murota H, Takahashi A, Yang L, Lee JB, Omiya K, et al. Dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3beta activation. J Invest Dermatol. 2014;134(2):326–34. https://doi.org/10.1038/jid.2013.323.CrossRefPubMed

76.

Murota H, Matsui S, Ono E, Kijima A, Kikuta J, Ishii M, et al. Sweat, the driving force behind normal skin: an emerging perspective on functional biology and regulatory mechanisms. J Dermatol Sci. 2015;77(1):3–10. https://doi.org/10.1016/j.jdermsci.2014.08.011.CrossRefPubMed

77.

Rerknimitr P, Tanizaki H, Yamamoto Y, Amano W, Nakajima S, Nakashima C, et al. Decreased filaggrin level may lead to sweat duct obstruction in filaggrin mutant mice. J Invest Dermatol. 2016;137:248–51. https://doi.org/10.1016/j.jid.2016.07.036.CrossRefPubMed

78.

Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–5. https://doi.org/10.1016/j.jaci.2007.04.031.CrossRefPubMedPubMedCentral

79.

Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332–7. https://doi.org/10.1016/j.clim.2007.11.006.CrossRefPubMed

80.

Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–77. e7. https://doi.org/10.1016/j.jaci.2015.03.051.CrossRefPubMed

81.

Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol. 2011;131(1):150–7. https://doi.org/10.1038/jid.2010.277.CrossRefPubMed

82.

Nygaard U, van den Bogaard EH, Niehues H, Hvid M, Deleuran M, Johansen C, et al. The “Alarmins” HMBG1 and IL-33 downregulate structural skin barrier proteins and impair epidermal growth. Acta Derm Venereol. 2017;97(3):305–12. https://doi.org/10.2340/00015555-2552.CrossRefPubMed

83.

Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2):426–33, 33.e1–8. https://doi.org/10.1016/j.jaci.2011.10.042.CrossRefPubMed

84.

Huth S, Schmitt L, Marquardt Y, Heise R, Luscher B, Amann PM et al. Effects of a ceramide-containing water-in-oil ointment on skin barrier function and allergen penetration in an IL-31 treated 3D model of the disrupted skin barrier. Exp Dermatol 2018;9:1009–14. https://doi.org/10.1111/exd.13697.CrossRefPubMed

85.

Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10):2511–4. https://doi.org/10.1038/jid.2010.161.CrossRefPubMed

86.

Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014;71(1):177–84. https://doi.org/10.1016/j.jaad.2014.01.891.CrossRefPubMed

87.

Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res. 2012;53(12):2755–66. https://doi.org/10.1194/jlr.P030338.CrossRefPubMedPubMedCentral

88.

Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol. 1991;96(4):523–6.CrossRefPubMed

89.

Yamamoto A, Serizawa S, Ito M, Sato Y. Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res. 1991;283(4):219–23.CrossRefPubMed

90.

Farwanah H, Raith K, Neubert RH, Wohlrab J. Ceramide profiles of the uninvolved skin in atopic dermatitis and psoriasis are comparable to those of healthy skin. Arch Dermatol Res. 2005;296(11):514–21. https://doi.org/10.1007/s00403-005-0551-2.CrossRefPubMed

91.

Angelova-Fischer I, Mannheimer AC, Hinder A, Ruether A, Franke A, Neubert RH, et al. Distinct barrier integrity phenotypes in filaggrin-related atopic eczema following sequential tape stripping and lipid profiling. Exp Dermatol. 2011;20(4):351–6. https://doi.org/10.1111/j.1600-0625.2011.01259.x.CrossRefPubMed

92.

Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27–30.CrossRefPubMed

93.

Bleck O, Abeck D, Ring J, Hoppe U, Vietzke JP, Wolber R, et al. Two ceramide subfractions detectable in Cer (AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema. J Invest Dermatol. 1999;113(6):894–900. https://doi.org/10.1046/j.1523-1747.1999.00809.x.CrossRefPubMed

94.

van Smeden J, Janssens M, Kaye EC, Caspers PJ, Lavrijsen AP, Vreeken RJ, et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol. 2014;23(1):45–52. https://doi.org/10.1111/exd.12293.CrossRefPubMed

95.

Tawada C, Kanoh H, Nakamura M, Mizutani Y, Fujisawa T, Banno Y, et al. Interferon-gamma decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis. J Invest Dermatol. 2014;134(3):712–8. https://doi.org/10.1038/jid.2013.364.CrossRefPubMed

96.

Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018;3(4). https://doi.org/10.1172/jci.insight.98006.

97.

Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002;119(1):166–73. https://doi.org/10.1046/j.1523-1747.2002.01833.x.CrossRefPubMed

98.

Park YH, Jang WH, Seo JA, Park M, Lee TR, Park YH, et al. Decrease of ceramides with very long-chain fatty acids and downregulation of elongases in a murine atopic dermatitis model. J Invest Dermatol. 2012;132(2):476–9. https://doi.org/10.1038/jid.2011.333.CrossRefPubMed

99.

Sasaki T, Shiohama A, Kubo A, Kawasaki H, Ishida-Yamamoto A, Yamada T, et al. A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. J Allergy Clin Immunol. 2013;132(5):1111–20. e4. https://doi.org/10.1016/j.jaci.2013.08.027.CrossRefPubMed

100.

Saunders SP, Goh CS, Brown SJ, Palmer CN, Porter RM, Cole C, et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol. 2013;132(5):1121–9. https://doi.org/10.1016/j.jaci.2013.08.046.CrossRefPubMedPubMedCentral

101.

• Brunner PM, Israel A, Zhang N, Leonard A, Wen HC, Huynh T, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094–106. https://doi.org/10.1016/j.jaci.2018.02.040. This article compares and contrasts the features of pediatric and adult atopic dermatitis. The differences in epidermal deraangement are of interest. CrossRefPubMed

102.

Danso M, Boiten W, van Drongelen V, Gmelig Meijling K, Gooris G, El Ghalbzouri A, et al. Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci. 2017;88(1):57–66. https://doi.org/10.1016/j.jdermsci.2017.05.005.CrossRefPubMed

103.

Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941–50. https://doi.org/10.1038/jid.2014.83.CrossRefPubMed

104.

Jang H, Matsuda A, Jung K, Karasawa K, Matsuda K, Oida K, et al. Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model. J Invest Dermatol. 2016;136(1):127–35. https://doi.org/10.1038/jid.2015.363.CrossRefPubMed

105.

Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol. 2005;125(3):510–20. https://doi.org/10.1111/j.0022-202X.2005.23838.x.CrossRefPubMed

106.

Kezic S, O'Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129(4):1031–9. e1. https://doi.org/10.1016/j.jaci.2011.12.989.CrossRefPubMedPubMedCentral

107.

Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–47. https://doi.org/10.1084/jem.20082242.CrossRefPubMedPubMedCentral

108.

Moniaga CS, Jeong SK, Egawa G, Nakajima S, Hara-Chikuma M, Jeon JE, et al. Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice. Am J Pathol. 2013;182(3):841–51. https://doi.org/10.1016/j.ajpath.2012.11.039.CrossRefPubMed

109.

Vasilopoulos Y, Sharaf N, di Giovine F, Simon M, Cork MJ, Duff GW, et al. The 3'-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA expression without altering its stability. J Dermatol Sci. 2011;61(2):131–3. https://doi.org/10.1016/j.jdermsci.2010.11.013.CrossRefPubMed

110.

Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141–2. https://doi.org/10.1038/75977.CrossRefPubMed

111.

Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet. 2001;29(2):175–8. https://doi.org/10.1038/ng728.CrossRefPubMed

112.

Zhao LP, Di Z, Zhang L, Wang L, Ma L, Lv Y, et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in northeast China. J Eur Acad Dermatol Venereol. 2012;26(5):572–7. https://doi.org/10.1111/j.1468-3083.2011.04120.x.CrossRefPubMed

113.

Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol. 2002;156(6):1099–111. https://doi.org/10.1083/jcb.200110122.CrossRefPubMedPubMedCentral

114.

De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773–86. e1–7. https://doi.org/10.1016/j.jaci.2010.10.018.CrossRefPubMed

115.

Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One. 2016;11(9):e0161759. https://doi.org/10.1371/journal.pone.0161759.CrossRefPubMedPubMedCentral

116.

Gruber R, Bornchen C, Rose K, Daubmann A, Volksdorf T, Wladykowski E, et al. Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. Am J Pathol. 2015;185(10):2777–89. https://doi.org/10.1016/j.ajpath.2015.06.021.CrossRefPubMed

117.

Yuki T, Komiya A, Kusaka A, Kuze T, Sugiyama Y, Inoue S. Impaired tight junctions obstruct stratum corneum formation by altering polar lipid and profilaggrin processing. J Dermatol Sci. 2013;69(2):148–58. https://doi.org/10.1016/j.jdermsci.2012.11.595.CrossRefPubMed

118.

• Yamaga K, Murota H, Tamura A, Miyata H, Ohmi M, Kikuta J, et al. Claudin-3 loss causes leakage of sweat from the sweat gland to contribute to the pathogenesis of atopic dermatitis. J Invest Dermatol. 2018;138(6):1279–87. https://doi.org/10.1016/j.jid.2017.11.040. This article emphasizes the importance of tight junction proteins in sweating. CrossRefPubMed

119.

Kelleher M, Dunn-Galvin A, Hourihane JO, Murray D, Campbell LE, McLean WH, et al. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol. 2015;135(4):930–5.e1. https://doi.org/10.1016/j.jaci.2014.12.013.CrossRefPubMedPubMedCentral

120.

Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–23. https://doi.org/10.1016/j.jaci.2014.08.005.CrossRefPubMedPubMedCentral

121.

Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–30. e6. https://doi.org/10.1016/j.jaci.2014.07.060.CrossRefPubMed

122.

Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (the BEEP trial): protocol for a randomised controlled trial. Trials. 2017;18(1):343. https://doi.org/10.1186/s13063-017-2031-3.CrossRefPubMedPubMedCentral

123.

van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:Cd012119. https://doi.org/10.1002/14651858.CD012119.pub2.CrossRefPubMed

124.

Grether-Beck S, Felsner I, Brenden H, Kohne Z, Majora M, Marini A, et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012;132(6):1561–72. https://doi.org/10.1038/jid.2012.42.CrossRefPubMedPubMedCentral

125.

Czarnowicki T, Malajian D, Khattri S, Correa da Rosa J, Dutt R, Finney R, et al. Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol. 2016;137(4):1091–102. e7. https://doi.org/10.1016/j.jaci.2015.08.013.CrossRefPubMed

126.

Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456–64. https://doi.org/10.1046/j.1523-1747.2003.12053.x.CrossRefPubMed

127.

Hatano Y, Elias PM, Crumrine D, Feingold KR, Katagiri K, Fujiwara S. Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol. 2011;131(9):1845–52. https://doi.org/10.1038/jid.2011.144.CrossRefPubMedPubMedCentral

128.

Lee SE, Choi Y, Kim SE, Noh EB, Kim SC. Differential effects of topical corticosteroid and calcineurin inhibitor on the epidermal tight junction. Exp Dermatol. 2013;22(1):59–61. https://doi.org/10.1111/exd.12055.CrossRefPubMed

129.

Jensen JM, Scherer A, Wanke C, Brautigam M, Bongiovanni S, Letzkus M, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy. 2012;67(3):413–23. https://doi.org/10.1111/j.1398-9995.2011.02747.x.CrossRefPubMed

130.

Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333–43.CrossRefPubMed

131.

Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014;170(4):914–21. https://doi.org/10.1111/bjd.12778.CrossRefPubMed

132.

Zhang C, Gurevich I, Aneskievich BJ. Organotypic modeling of human keratinocyte response to peroxisome proliferators. Cells Tissues Organs. 2012;196(5):431–41. https://doi.org/10.1159/000336268.CrossRefPubMed

133.

Kim H, Lim YJ, Park JH, Cho Y. Dietary silk protein, sericin, improves epidermal hydration with increased levels of filaggrins and free amino acids in NC/Nga mice. Br J Nutr. 2012;108(10):1726–35. https://doi.org/10.1017/s0007114511007306.CrossRefPubMed

134.

Hou M, Sun R, Hupe M, Kim PL, Park K, Crumrine D, et al. Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms. Exp Dermatol. 2013;22(3):210–5. https://doi.org/10.1111/exd.12102.CrossRefPubMedPubMedCentral

135.

Elias PM. Primary role of barrier dysfunction in the pathogenesis of atopic dermatitis. Exp Dermatol. 2018;8:847–51. https://doi.org/10.1111/exd.13693.CrossRefPubMed

136.

Man MM, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol. 1996;106(5):1096–101.CrossRef

137.

Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633–43. https://doi.org/10.1016/j.jaci.2017.07.006.CrossRefPubMed

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Skin Barrier Function and Atopic Dermatitis

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions

Use of Lasers in Wound Healing: How to Best Utilize Laser Technology to Prevent Scar Formation

Immunology of Wound Healing

The Skin Microbiome in Atopic Dermatitis—a Potential Treatment Target?

Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis

Updates on Immunotherapy for the Treatment of Skin Cancer